Beigene, LTD 8-K filings

BeOne Medicines Ltd. has finalized a statutory tax audit in China, resulting in a significant settlement payment to be recognized in its second-quarter financial results.

BeOne Medicines Ltd. shareholders approved key proposals at the 2026 Annual General Meeting, including updated incentive and share purchase plans, director elections, and financial statements.

The FDA has granted accelerated approval to BEQALZI (sonrotoclax) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

BeOne Medicines announced a 35% increase in total revenue to $1.5 billion for the first quarter of 2026, driven by significant growth in its foundational BRUKINSA drug.

BeOne Medicines Ltd. disclosed its 2025 financial results in a Shanghai Stock Exchange filing, highlighting a 40% revenue surge and significant R&D investment in its oncology pipeline.

BeOne Medicines announced robust fourth quarter and full year 2025 financial results, driven by significant global revenue growth of BRUKINSA and positive pipeline advancements.

BeOne Medicines Ltd. announced the full repayment and termination of its credit facility with China Merchants Bank, incurring no penalties.

BeOne Medicines Ltd. announced the appointment of Dr. Lai Wang as President, Global Head of Research and Development, effective January 1, 2026.

BeOne Medicines Ltd. has secured a new senior secured financing package totaling approximately $1 billion, comprising revolving and term loan facilities for general corporate purposes and refinancing.

BeOne Medicines Ltd. announced robust third-quarter 2025 financial results, driven by strong BRUKINSA sales and significant pipeline advancements, leading to a positive outlook.

BeOne Medicines Ltd. filed its 2025 Interim Report with the STAR Market, providing U.S. GAAP R&D expense allocations and outlining key differences between PRC and U.S. accounting standards.

BeOne Medicines has entered into a Royalty Purchase Agreement with Royalty Pharma for up to $950 million for its Imdelltra ex-China royalty rights.

BeOne Medicines Ltd. reported a strong second quarter 2025, with total revenues increasing 42% to $1.3 billion, driven by robust BRUKINSA sales and positive GAAP net income.

BeOne Medicines Ltd., formerly BeiGene, Ltd., has successfully completed its re-domiciliation from the Cayman Islands to Switzerland, effective May 27, 2025, alongside updating its deposit agreement, corporate governance documents, and executive employment contracts.

BeiGene held its Annual Meeting of Shareholders on May 21, 2025, where shareholders voted on key resolutions, including the re-election of directors, ratification of auditors, and approval of share issuance and repurchase mandates.

BeiGene enters into an internal transfer agreement to issue 133 million ordinary shares in preparation for its proposed re-domiciliation from the Cayman Islands to Switzerland.

BeiGene reports a strong first quarter in 2025, achieving GAAP profitability and a 49% increase in total revenues, driven by robust BRUKINSA sales.

BeiGene successfully invalidated all challenged claims of Pharmacyclics' U.S. Patent related to BRUKINSA (zanubrutinib) following a post-grant review.

BeiGene shareholders voted to approve the company's deregistration in the Cayman Islands and continuation to Switzerland at an Extraordinary General Meeting held on April 28, 2025.

BeiGene's 2024 Annual Report, filed with the Shanghai Stock Exchange, reveals financial details under PRC GAAP and outlines key differences compared to U.S. GAAP.

BeiGene reports significant revenue growth for Q4 and full year 2024, driven by BRUKINSA sales, and forecasts positive GAAP operating income and cash flow generation in 2025.

BeiGene announced it anticipates achieving positive operating income for the full year 2025, based on U.S. GAAP.

BeiGene, Ltd. will change its Nasdaq ticker symbol from BGNE to ONC effective January 2, 2025.

BeiGene has entered into a new $400 million credit facility agreement with China Merchants Bank to support its daily operations and refinance existing debt.

BeiGene has reached a settlement with MSN Pharmaceuticals, allowing a generic version of BRUKINSA to enter the U.S. market no earlier than June 15, 2037, resolving all outstanding patent litigation related to the drug.

BeiGene, Ltd. has announced its intention to change its name to BeOne Medicines Ltd., pending shareholder approval, to reflect its commitment to developing innovative cancer treatments.

BeiGene announced a successful third quarter of 2024, highlighted by $1 billion in total revenue and significant growth in BRUKINSA sales.

BeiGene, Ltd. reports the passing of independent director Donald W. Glazer, who had served on the board since 2013.

BeiGene has updated its risk factors disclosure in response to a request from the SEC regarding legal and operational risks associated with its China operations.

BeiGene, a global oncology company, has appointed Shalini Sharp to its Board of Directors and Audit Committee, effective September 27, 2024.